Insider Trading

Notable insider buying and selling activity across public companies.

Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.

Articles

475 total articles

Axsome Therapeutics' Chief Commercial Officer Executes Share Sale and Option Exercise Amid Growth Indicators

Axsome Therapeutics' Chief Commercial Officer Executes Share Sale and Option Exercise Amid Growth Indicators

Ari Maizel, Chief Commercial Officer of Axsome Therapeutics Inc, conducted a significant stock sale alongside exercising options, against a backdrop of notable revenue growth and positive analyst sentiment. The transactions occurred while Axsome's shares traded near yearly highs, underscoring investor interest amid the company's expanding commercia…

Procore Director Kevin J. O’Connor Sells Nearly $1 Million in Shares Amid Strategic Corporate Moves

Procore Director Kevin J. O’Connor Sells Nearly $1 Million in Shares Amid Strategic Corporate Moves

Kevin J. O’Connor, a director at Procore Technologies, has sold approximately $984,268 worth of company shares through a planned trading program, while Procore strengthens its market position through acquisitions and favorable analyst reviews. The company recently acquired Datagrid to enhance AI capabilities, saw positive analyst upgrades tied to a…

Dakota Gold Corp. Updates Leadership and Gains Positive Broker Outlook

Dakota Gold Corp. Updates Leadership and Gains Positive Broker Outlook

Dakota Gold Corp. has recently announced key organizational and market developments, including a change in its independent auditor to Deloitte & Touche LLP, the finalization of a CEO employment contract, and the initiation of coverage by Freedom Capital Markets with a Buy rating and price target of $8.40. These moves underscore the company’s strate…

Dakota Gold CFO Executes Significant Share Transactions and Company Announces Key Corporate Developments

Dakota Gold CFO Executes Significant Share Transactions and Company Announces Key Corporate Developments

On January 21, 2026, Dakota Gold Corp.'s Chief Financial Officer, Shawn Campbell, sold 55,000 shares of the company's common stock, generating approximately $346,291 in proceeds. This transaction was conducted with share prices ranging between $6.225 and $6.44. Subsequently, Campbell's spouse retains indirect ownership of 296,736 shares while Campb…

BlackRock Senior Managing Director Kushel J. Richard Conducts $22.5 Million Share Sale and Exercises Stock Options

BlackRock Senior Managing Director Kushel J. Richard Conducts $22.5 Million Share Sale and Exercises Stock Options

Kushel J. Richard, Senior Managing Director at BlackRock, executed a notable stock sale of 20,000 shares valued at $22.5 million and simultaneously exercised options to acquire an additional 20,000 shares at a considerably lower price. These transactions come amid BlackRock’s recent strong financial performance and optimistic analyst revisions, fur…

Acumen Pharmaceuticals CEO Offloads Shares to Manage Tax Obligations Amid Ongoing Alzheimer’s Drug Trials

Acumen Pharmaceuticals CEO Offloads Shares to Manage Tax Obligations Amid Ongoing Alzheimer’s Drug Trials

Daniel Joseph O’Connell, CEO of Acumen Pharmaceuticals, completed the sale of over 12,000 shares to satisfy tax liabilities tied to restricted stock units, under a pre-established trading plan. The company, focused on Alzheimer’s treatments, recently reported a net loss but continues progress in its clinical trials and collaboration with JCR Pharma…

Acumen Pharmaceuticals CFO Executes Stock Sale to Meet Tax Liabilities Amid Ongoing Alzheimer’s R&D Initiatives

Acumen Pharmaceuticals CFO Executes Stock Sale to Meet Tax Liabilities Amid Ongoing Alzheimer’s R&D Initiatives

Matt Zuga, Chief Financial Officer of Acumen Pharmaceuticals, completed stock sales totaling 4,160 shares valued at approximately $7,600 in late January 2026. These transactions were made to satisfy tax withholding obligations linked to vested restricted stock units, following a Rule 10b5-1 plan. Acumen remains focused on progressing Alzheimer’s tr…

Lindblad Expeditions Director Sven-Olof Completes Significant Stock Sale Amid Strong Market Performance

Lindblad Expeditions Director Sven-Olof Completes Significant Stock Sale Amid Strong Market Performance

On January 22, 2026, Lindblad Sven-Olof, a director and substantial shareholder of Lindblad Expeditions Holdings, Inc., sold 62,100 shares of the company's common stock, executing the transaction near the 52-week high price. The sale was conducted under a Rule 10b5-1 trading plan, generating proceeds exceeding $1 million. Amidst revenue growth and …

Acumen Pharmaceuticals Executive Executes Share Sales Totaling $16,720 Amid Alzheimer’s Drug Development Progress

Acumen Pharmaceuticals Executive Executes Share Sales Totaling $16,720 Amid Alzheimer’s Drug Development Progress

Derek M Meisner, Chief Legal Officer and Corporate Secretary of Acumen Pharmaceuticals, Inc., has conducted stock sales totaling $16,720 over three days in January 2026 under a pre-planned trading arrangement. These transactions come as the company continues to focus on its Alzheimer's treatment pipeline, including progressing clinical trials and c…

Ionis Pharmaceuticals Executive Vice President Divests $323,490 in Equity Amid Robust Stock Performance

Ionis Pharmaceuticals Executive Vice President Divests $323,490 in Equity Amid Robust Stock Performance

Shannon L. Devers, Executive Vice President and Chief Human Resources Officer at Ionis Pharmaceuticals, completed a sale of nearly $323,500 worth of stock in late January 2026. The transaction occurred near the company’s 52-week high and precedes an anticipated earnings announcement. Meanwhile, Ionis continues progressing with recent regulatory app…